Potential pharmacodynamic substances of Laportea bulbifera in treatment of rheumatoid arthritis based on serum pharmacochemistry and pharmacology.
10.19540/j.cnki.cjcmm.20220609.201
- Author:
Juan TANG
1
;
Qing ZHANG
2
;
Dan WU
2
;
Si-Ying CHEN
2
;
Yi CHEN
2
;
Yue-Ting LI
2
;
Lin ZHENG
2
;
Yong HUANG
2
;
Yan-Yu LAN
2
;
Yong-Lin WANG
2
;
Zi-Peng GONG
2
Author Information
1. Provincial Key Laboratory of Pharmaceutics in Guizhou Province, Engineering Research Center for the Development and Application of Ethnic Medicine and Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University Guiyang 550004, China Center for Drug Inspection,Guizhou Medical Products Administration Guiyang 550081, China.
2. Provincial Key Laboratory of Pharmaceutics in Guizhou Province, Engineering Research Center for the Development and Application of Ethnic Medicine and Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University Guiyang 550004, China.
- Publication Type:Journal Article
- Keywords:
Laportea bulbifera;
MH7A cells;
serum pharmacochemistry;
serum pharmacology;
spectrum-effect relationship
- MeSH:
Animals;
Arthritis, Experimental/drug therapy*;
Arthritis, Rheumatoid/drug therapy*;
Chlorogenic Acid/analogs & derivatives*;
Cytokines/metabolism*;
Dinoprostone;
Humans;
Interleukin-1beta/genetics*;
Interleukin-6;
Plant Extracts/therapeutic use*;
Quinic Acid/analogs & derivatives*;
Rutin;
Tumor Necrosis Factor-alpha/metabolism*;
Urticaceae/chemistry*
- From:
China Journal of Chinese Materia Medica
2022;47(17):4755-4764
- CountryChina
- Language:Chinese
-
Abstract:
The present study investigated the pharmacodynamic material basis of Laportea bulbifera in the treatment of rheumatoid arthritis. Firstly, human rheumatoid arthritis fibroblast-like synoviocyte line MH7A was cultured in vitro and treated with tumor necrosis factor alpha(TNF-α, 50 ng·mL~(-1)). The proliferation and the levels of inflammatory cytokines such as prostaglandin E2(PGE2), interleukin-1β(IL-1β), and interleukin-6(IL-6) of the MH7A cells exposed to the serum containing L. bulbifera were determined to evaluate the anti-rheumatoid arthritis effects of the serum. Furthermore, the ultra-performance liquid chromatography tandem mass spectrometry fingerprints of the L. bulbifera crude extract, the drug-containing serum, and the drug-free serum were compared to identify the compounds newly generated in the serum after oral administration of the extract. According to the peak areas of common peaks and the results of anti-rheumatoid arthritis effect test, the active components were identified. The serum containing L. bulbifera significantly inhibited the proliferation of the MH7A cells activated by TNF-α and the expression of PGE2, IL-6, and IL-1β. Thirty newly generated compounds were detected in the drug-containing serum. Among them, neochlorogenic acid, cryptochlorogenic acid, chlorogenic acid, rutin, isoquercitrin, luteoloside, kaempferol-3-O-rutinoside, and quercitrin were also present in the crude extract. Twelve characteristic peaks(3, 7, 8, 14, 18, 19, 21, 23, 24, m6, m7, and m15) were significantly correlated with the pharmaceutical effect. According to the correlations, neochlorogenic acid, cryptochlorogenic acid, and chlorogenic acid had great contributions to the anti-rheumatoid arthritis activity. This study preliminarily clarified the potential pharmacodynamic substances of L. bulbifera in the treatment of rheumatoid arthritis, which laid a theoretical and experimental foundation for further development and application of the medicinal plant.
